3,833 results
Search Results
2. The use of biomarkers to stratify surgical care in women with ovarian cancer: Scientific Impact Paper No. 69 May 2022.
- Author
-
Phelps, D. L., Borley, J. V., Brown, R., Takáts, Z., and Ghaem‐Maghami, S.
- Subjects
- *
OVARIAN cancer , *CANCER patients , *CA 125 test , *BIOMARKERS , *BIOMOLECULES , *CANCER prognosis , *CANCER treatment - Abstract
Plain language summary: Biomarkers may offer unforeseen insights into clinical diagnosis, as well as the likely course and outcome of a condition. In this paper, the focus is on the use of biological molecules found in body fluids or tissues for diagnosis and prediction of outcome in ovarian cancer patients. In cancer care, biomarkers are being used to develop personalised treatment plans for patients based on the unique characteristics of their tumour. This tailoring of care can be used to pursue specific targets identified by biomarkers, or treat the patient according to specific tumour characteristics. Surgery is one of the core treatments for ovarian cancer, whether it is offered in primary surgery or following chemotherapy in delayed surgery. Biomarkers already exist to guide the treatment of tumours with chemotherapy, but very little research has determined the value of biomarkers in tailoring surgical care for ovarian cancer. Such research is required to identify new biomarkers and assess their effectiveness in a clinical setting as well as to help identify specific tumour types to guide surgery. Biomarkers could help to determine the success of removing the disease surgically, or help to identify tumour deposits that persist after chemotherapy. All of these aspects would improve current practice. This Scientific Impact Paper highlights research that may pave the way towards bespoke surgery according to the biological characteristics of a tumour and aid gynaecological oncologists to provide surgical treatment according to individual need, rather than a blanket approach for all. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Findings from IRCCS Foundation National Cancer Institute Provides New Data on Angiosarcomas (Clinical Recommendations for Treatment of Localized Angiosarcoma: a Consensus Paper By the Italian Sarcoma Group).
- Subjects
SARCOMA ,ANGIOSARCOMA ,CANCER chemotherapy ,MEDICAL societies ,CANCER treatment ,REPORTERS & reporting - Abstract
A consensus paper by the Italian Sarcoma Group provides clinical recommendations for the treatment of localized angiosarcoma, a rare and aggressive vascular sarcoma. The paper highlights the unique challenges in managing angiosarcoma compared to other sarcomas and emphasizes the need for dedicated clinical recommendations. The Italian Sarcoma Group organized a consensus meeting to develop these recommendations, aiming to standardize and harmonize clinical practices for the optimal approach to localized angiosarcoma. The research concludes that further investigation through clinical trials is necessary to address uncertainties in the management of the disease. [Extracted from the article]
- Published
- 2024
4. Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022.
- Author
-
Robijns, Jolien, Nair, Raj G., Lodewijckx, Joy, Arany, Praveen, Barasch, Andrei, Bjordal, Jan M., Bossi, Paolo, Chilles, Anne, Corby, Patricia M., Epstein, Joel B., Elad, Sharon, Fekrazad, Reza, Fregnani, Eduardo Rodrigues, Genot, Marie-Thérèse, Ibarra, Ana M. C., Hamblin, Michael R., Heiskanen, Vladimir, Hu, Ken, Klastersky, Jean, and Lalla, Rajesh
- Subjects
PHOTOBIOMODULATION therapy ,TRISMUS ,HEMATOPOIETIC stem cell transplantation ,CANCER treatment ,VOICE disorders ,HAND-foot syndrome ,ORAL medicine - Abstract
Disclaimer: This article is based on recommendations from the 12th WALT Congress, Nice, October 3-6, 2018, and a follow-up review of the existing data and the clinical observations of an international multidisciplinary panel of clinicians and researchers with expertise in the area of supportive care in cancer and/or PBM clinical application and dosimetry. This article is informational in nature. As with all clinical materials, this paper should be used with a clear understanding that continued research and practice could result in new insights and recommendations. The review reflects the collective opinion and, as such, does not necessarily represent the opinion of any individual author. In no event shall the authors be liable for any decision made or action taken in reliance on the proposed protocols. Objective: This position paper reviews the potential prophylactic and therapeutic effects of photobiomodulation (PBM) on side effects of cancer therapy, including chemotherapy (CT), radiation therapy (RT), and hematopoietic stem cell transplantation (HSCT). Background: There is a considerable body of evidence supporting the efficacy of PBM for preventing oral mucositis (OM) in patients undergoing RT for head and neck cancer (HNC), CT, or HSCT. This could enhance patients’ quality of life, adherence to the prescribed cancer therapy, and treatment outcomes while reducing the cost of cancer care. Methods: A literature review on PBM effectiveness and dosimetry considerations for managing certain complications of cancer therapy were conducted. A systematic review was conducted when numerous randomized controlled trials were available. Results were presented and discussed at an international consensus meeting at the World Association of photobiomoduLation Therapy (WALT) meeting in 2018 that included world expert oncologists, radiation oncologists, oral oncologists, and oral medicine professionals, physicists, engineers, and oncology researchers. The potential mechanism of action of PBM and evidence of PBM efficacy through reported outcomes for individual indications were assessed. Results: There is a large body of evidence demonstrating the efficacy of PBM for preventing OM in certain cancer patient populations, as recently outlined by the Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Building on these, the WALT group outlines evidence and prescribed PBM treatment parameters for prophylactic and therapeutic use in supportive care for radiodermatitis, dysphagia, xerostomia, dysgeusia, trismus, mucosal and bone necrosis, lymphedema, hand-foot syndrome, alopecia, oral and dermatologic chronic graft-versushost disease, voice/speech alterations, peripheral neuropathy, and late fibrosis amongst cancer survivors. Conclusions: There is robust evidence for using PBM to prevent and treat a broad range of complications in cancer care. Specific clinical practice guidelines or evidence-based expert consensus recommendations are provided. These recommendations are aimed at improving the clinical utilization of PBM therapy in supportive cancer care and promoting research in this field. It is anticipated these guidelines will be revised periodically. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Evidence-Based Dietetic Practice: EFAD Discussion Paper on Challenges for Implementation, Education, Research, and Lifelong Learning.
- Subjects
CONTINUING education ,CANCER patient care ,PHYSICAL activity ,HEALTH outcome assessment ,CANCER treatment - Published
- 2023
- Full Text
- View/download PDF
6. Overcoming barriers to timely recognition and treatment of cancer cachexia: Sharing Progress in Cancer Care Task Force Position Paper and Call to Action.
- Author
-
Arends, Jann, Muscaritoli, Maurizio, Anker, Stefan, Audisio, Riccardo, Barazzoni, Rocco, Bosnjak, Snezana, Bossi, Paolo, Bowman, Jacqueline, Gijssels, Stefan, Krznarić, Željko, Strasser, Florian, and Aapro, Matti
- Subjects
- *
CACHEXIA , *TASK forces , *CANCER treatment , *MUSCLE mass , *SKELETAL muscle - Abstract
Cachexia is a life-threatening disorder affecting an estimated 50–80% of cancer patients. The loss of skeletal muscle mass in patients with cachexia is associated with an increased risk of anticancer treatment toxicity, surgical complications and reduced response. Despite international guidelines, the identification and management of cancer cachexia remains a significant unmet need owing in part to the lack of routine screening for malnutrition and suboptimal integration of nutrition and metabolic care into clinical oncology practice. In June 2020, Sharing Progress in Cancer Care (SPCC) convened a multidisciplinary task force of medical experts and patient advocates to examine the barriers preventing the timely recognition of cancer cachexia, and provide practical recommendations to improve clinical care. This position paper summarises the key points and highlights available resources to support the integration of structured nutrition care pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Title of presented paper: Chemobrain after anticancer treatment - when the necessary treatment has unpleasant consequences.
- Author
-
Monika, Błądek, Karolina, Drygała, and Gabriela, Barszcz
- Subjects
ANTINEOPLASTIC agents ,CANCER treatment ,COGNITION ,COGNITION disorders ,IMMUNOTHERAPY - Abstract
Introduction and aim. Over the last few decades, there has been tremendous progress in the treatment of cancer. Unfortunately, anti-cancer therapies, although necessary and increasingly effective, still carry many side effects. One of these effects is the chemobrain -- cognitive disorders resulting from strong chemotherapy. The aim of this paper is to review available knowledge of chemobrain. Material and methods. The paper reviews articles available in the PubMed medical database, searched with the phrases "chemobrain", "chemobrain cancer" from the years 2015-2023 which are reviews, systematic reviews or meta-analyses. 41 results were obtained, of which 13 articles were used for the final analysis after the selection of papers strictly related to the issue of chemobrain. Analysis of literature. The occurrence of chemobrain is associated with impaired cognitive abilities, problems with concentration, and memory loss. It may occur only during treatment or persist even after its completion. According to the data, chemobrain occurs much more often as a complication of traditional chemotherapy than in the case of immunotherapy. The mechanism of chemobrain formation is not known. A combination of oxygen radical production and cytokine dysregulation is suspected as an inducer of this complication. Chemobrain treatment strategies remain under development. At the moment, non-pharmacological methods are used in the treatment, such as regular physical exercise, mental exercise, or a diet including omega-3 fatty acids. Pharmacological treatment is still under development and research. Conclusion. Chemobrain is a medical complication that can have a serious psychological impact on patients undergoing anti-cancer therapy, so further research is needed to better understand the mechanism of this phenomenon, which will allow the development of new treatments and possible ways to prevent the occurrence of chemobrain. [ABSTRACT FROM AUTHOR]
- Published
- 2023
8. Upgrading the Chemotherapy Consent: Trading in Paper for Tablet.
- Author
-
Wu, Lesley, Smith, Cardinale B., Parra, Jessica, Liu, Mark, Theroux, Haley Hines, and Bhardwaj, Aarti S.
- Subjects
AUDITING ,SPECIALTY hospitals ,PROBLEM solving ,CANCER chemotherapy ,INFORMED consent (Medical law) ,CANCER patients ,CANCER treatment ,HUMAN services programs ,HEALTH care teams ,DESCRIPTIVE statistics ,PATIENT compliance ,MEDICAL needs assessment ,BREAST tumors - Abstract
PURPOSE Our institution participated in the Oncology Care Model, which required us to include many of the 13 elements of the National Academy of Medicine (NAM) care plan into care pathways for our patients. We optimized our existing chemotherapy consent process to meet this need and maximized completion. METHODS Our multidisciplinary committee developed a three-phase Plan-Do-Study-Act process in our breast cancer clinic: (1) update and educate providers on our paper chemotherapy form with multiple components of the NAM care plan including prognosis and treatment effects on quality of life; (2) piloted an electronic chemotherapy consent form to decrease the administrative burden; and (3) autopopulated fields within the electronic consent. We assessed feedback after cycle 1 and created a Pareto chart. The outcome measure was percent completion of chemotherapy consent documents. RESULTS Baseline monthly random chart audit of 40 patients revealed 20% of paper chemotherapy consent forms were completed in their entirety among patients. When we re-educated clinicians about the new paper consent containing the NAM elements, compliance rose to nearly 30%. A Pareto chart confirmed that content redundancy and wordiness were leading to under-completion. After creating and piloting the electronic consent, compliance increased to 90%. Finally, autopopulation with drop-down selections increased and sustained completion to 100%. CONCLUSION Incorporating regulatory requirements into an existing workflow using Plan-Do-Study-Act methodology can reduce administrative burden on clinicians. Additional use of innovative technology can further increase clinician compliance with regulatory requirements while delivering high-value quality care to patients with cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Examining Guidelines and New Evidence in Oncology Nutrition: a Position Paper on Gaps and Opportunities in Multimodal Approaches to Improve Patient Care.
- Author
-
Prado, Carla M., Laviano, Alessandro, Gillis, Chelsia, Sung, Anthony D., Gardner, Maureen, Yalcin, Suayib, Dixon, Suzanne, Newman, Shila M., Bastasch, Michael D., Sauer, Abby C., Hegazi, Refaat, and Chasen, Martin R.
- Subjects
NUTRITION ,PATIENT care ,MUSCLE mass ,HEALTH outcome assessment ,CANCER treatment - Abstract
Malnutrition, muscle loss, and cachexia are prevalent in cancer and remain key challenges in oncology today. These conditions are frequently underrecognized and undertreated and have devastating consequences for patients. Early nutrition screening/assessment and intervention are associated with improved patient outcomes. As a multifaceted disease, cancer requires multimodal care that integrates supportive interventions, specifically nutrition and exercise, to improve nutrient intake, muscle mass, physical functioning, quality of life, and treatment outcomes. An integrated team of healthcare providers that incorporates societies' recommendations into clinical practice can help achieve the best possible outcomes. A multidisciplinary panel of experts in oncology, nutrition, exercise, and medicine participated in a 2-day virtual roundtable in October 2020 to discuss gaps and opportunities in oncology nutrition, alone and in combination with exercise, relative to current evidence and international societies' recommendations. The panel recommended five principles to optimize clinical oncology practice: (1) position oncology nutrition at the center of multidisciplinary care; (2) partner with colleagues and administrators to integrate a nutrition care process into the multidisciplinary cancer care approach; (3) screen all patients for malnutrition risk at diagnosis and regularly throughout treatment; (4) combine exercise and nutrition interventions before (e.g., prehabilitation), during, and after treatment as oncology standard of care to optimize nutrition status and muscle mass; and (5) incorporate a patient-centered approach into multidisciplinary care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Reports Outline Heart Attack Study Results from Institute for Cancer Research and Treatment (IRCCS) San Raffaele Scientific Institute (Clinical Paper Organ Donation After Extracorporeal Cardiopulmonary Resuscitation for Refractory...).
- Subjects
CARDIOPULMONARY resuscitation ,ORGAN donation ,CANCER treatment ,CANCER research ,RESEARCH institutes ,MYOCARDIAL infarction - Abstract
A recent study conducted in Milan, Italy, examined the impact of organ donation in patients who received extracorporeal cardiopulmonary resuscitation (ECPR) for refractory out-of-hospital cardiac arrest (OHCA). The study found that among 307 adults treated with ECPR, 19% of patients were eligible for organ donation, contributing a total of 167 solid organs. The research suggests that when ECPR fails in patients with refractory OHCA, organ donation after brain or circulatory death can benefit a significant number of patients awaiting transplantation. The study emphasizes the importance of ECPR selection criteria in determining the number of potential organ donors. [Extracted from the article]
- Published
- 2024
11. New Breast Cancer Data Have Been Reported by Researchers at Ajman University (Paper Enhancing Photodynamic Therapy Efficacy Through Silica Nanoparticle-mediated Delivery of Temoporfin for Targeted In Vitro Breast Cancer Treatment).
- Subjects
PHOTODYNAMIC therapy ,BREAST cancer ,CANCER treatment ,RESEARCH personnel ,TECHNOLOGICAL innovations - Abstract
Researchers at Ajman University in the United Arab Emirates have conducted a study on enhancing the efficacy of photodynamic therapy (PDT) for breast cancer treatment. The study focuses on the use of silica nanoparticles (SiNPs) to encapsulate a photosensitizer called Temoporfin, which aims to improve its delivery and reduce toxicity. The researchers found that encapsulated Temoporfin demonstrated greater effectiveness in eliminating cancer cells compared to its naked form. This research highlights the potential of SiNPs as an efficient drug delivery system in PDT and sets the groundwork for more advanced strategies in cancer treatment. [Extracted from the article]
- Published
- 2024
12. Dana-Farber Moves to Retract, Correct Dozens of Cancer Papers Amid Allegations.
- Author
-
Worcester, Sharon
- Subjects
DISMISSAL of employees ,SPECIALTY hospitals ,FRAUD in science ,ARTIFICIAL intelligence ,CANCER treatment ,MULTIPLE myeloma ,MEDICAL research - Abstract
The article focuses on Dana-Farber Cancer Institute's actions to retract at least six research papers and correct 31 others following allegations of data manipulation, including papers authored by high-ranking officials on topics such as multiple myeloma and immune cells. Topics include the investigation sparked by a blog post highlighting image manipulation and errors in nearly 60 papers published between 1997 and 2017, and the specific irregularities noted by the blogger.
- Published
- 2024
13. Use Cases Requiring Privacy-Preserving Record Linkage in Paediatric Oncology.
- Author
-
Hayn, Dieter, Kreiner, Karl, Sandner, Emanuel, Baumgartner, Martin, Jammerbund, Bernhard, Falgenhauer, Markus, Düster, Vanessa, Devi-Marulkar, Priyanka, Schleiermacher, Gudrun, Ladenstein, Ruth, and Schreier, Guenter
- Subjects
CANCER treatment ,TUMORS in children ,DATABASE management ,PRIVACY ,MEDICAL record linkage ,CHILDREN'S hospitals ,MEDICAL ethics ,SPECIALTY hospitals - Abstract
Simple Summary: Large datasets concerning childhood cancers are rare. Therefore, it is important to fully exploit all available data, which are distributed over several resources, including biomaterials, images, clinical trials, and registries. With privacy-preserving record linkage (PPRL), datasets can be merged, without disclosing the patients' identities. Although PPRL is already implemented or described in various settings, use case descriptions are fragmented and incomplete. The present paper gives an overview of current and future use cases of PPRL in childhood cancer. We screened the literature, projects, and trial protocols, analysed a hypothetical patient journey, and discussed use cases with experts. All the identified use cases were structured along six key dimensions. We conclude that PPRL is a key concept in childhood cancer. Therefore, PPRL strategies should already be considered when starting research projects, to avoid distributed data silos, to maximise the knowledge derived from collected data, and, ultimately, to improve outcomes for children with cancer. Large datasets in paediatric oncology are inherently rare. Therefore, it is paramount to fully exploit all available data, which are distributed over several resources, including biomaterials, images, clinical trials, and registries. With privacy-preserving record linkage (PPRL), personalised or pseudonymised datasets can be merged, without disclosing the patients' identities. Although PPRL is implemented in various settings, use case descriptions are currently fragmented and incomplete. The present paper provides a comprehensive overview of current and future use cases for PPRL in paediatric oncology. We analysed the literature, projects, and trial protocols, identified use cases along a hypothetical patient journey, and discussed use cases with paediatric oncology experts. To structure PPRL use cases, we defined six key dimensions: distributed personalised records, pseudonymisation, distributed pseudonymised records, record linkage, linked data, and data analysis. Selected use cases were described (a) per dimension and (b) on a multi-dimensional level. While focusing on paediatric oncology, most aspects are also applicable to other (particularly rare) diseases. We conclude that PPRL is a key concept in paediatric oncology. Therefore, PPRL strategies should already be considered when starting research projects, to avoid distributed data silos, to maximise the knowledge derived from collected data, and, ultimately, to improve outcomes for children with cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Title of presented paper: Melatonin in cancer treatment.
- Author
-
Dyndał, Kinga, Czerkiewicz, Karolina, and Cybula, Paweł
- Subjects
MELATONIN ,CANCER treatment ,NEUROHORMONES ,HORMONE therapy ,RADIOTHERAPY - Abstract
Introduction and aim. Melatonin, a neurohormone involved in the regulation of the sleep-wake cycle, is produced in the human body, mainly in the pineal gland. An increasing number of evidence, suggests that this amine may be an essential new target (adjuvant) in cancer treatment. The oncostatic and anticancer properties of melatonin have been demonstrated in various types of cancer. The tumor suppressive function of melatonin is exerted through different interactions with cell surface receptors such as MT1 and MT2 melatonin receptors. Material and methods. A literature review was performed by analyzing randomized controlled trials (RCTs) and systematic reviews from PubMed/MEDLINE and Embase published in the last five years. For the literature search, we used the following keywords: *melatonin in cancer, *novel cancer therapy, and *hormonal therapy. Analysis of literature. Studies have shown that melatonin may induce anti-tumor effects through multiple mechanisms, including inhibition of tumor growth and angiogenesis, induction of apoptosis, inhibition of cell proliferation, modulation of the immune response, and augmentation of the therapeutic effects of conventional anticancer therapies. In addition, melatonin decreased some of the side effects caused by radiotherapy and chemotherapy, such as asthenia, thrombocytopenia, leukopenia, and nausea. Conclusion. Melatonin may improve sleep and quality of life in cancer patients, relieve anxiety in most patients, and reduce the risk of developing depressive symptoms. Melatonin has also shown great potential as a safe and effective complementary therapy for cancer treatment with minimal side effects and low toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
15. Investigating the potential application of organic and non-organic nanoparticles for gastric cancer treatment: An evidence-based review.
- Author
-
Moradifar, N., Moayyedkazemi, A., Mohammadi, H. R., Ahmadi, S., and Raziani, Y.
- Subjects
STOMACH cancer ,NANOPARTICLES ,METAL nanoparticles ,CANCER treatment ,CANCER-related mortality - Abstract
Gastric cancer, which is considered a major health concern, is the sixth most frequent cancer and the second leading cause of cancer-related mortality across the globe. The present survey aimed to systematically review the anti-gastric cancer effect of all organic and inorganic nanoparticles (NPs) in in vitro, in vivo, and clinical trials. The investigation followed the PRISMA guidelines, and the findings were recorded in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-Analysis Facility database. A detailed search was conducted on various English databases, such as Scopus, Web of Science, EMBASE, PubMed, and Google Scholar, with no specified publication time frame to obtain papers regarding the anti-gastric cancer properties of nanoparticles. The search process was performed using the following terms: "Nanoparticles," "Gastric cancer," "Antigastric cancer," "Metal nanoparticles," "Organic nanoparticles," "Inorganic nanoparticles, "in vitro," "Clinical," and "in vivo,". Out of 11,189 papers, 31 articles, including 19 (45.5%) in vitro, 3 (13.6%) in vivo, 3 (13.6%) clinical trials, and 6 (27.3%) in vitro/in vivo, up to 2023, met the inclusion criteria for discussion in this systematic review. The most widely used NPs were found to be organic nanoparticles, such as polylactic acid and poly lactic-co-glycolic acid (16, 80.0%), followed by inorganic nanoparticles, such as silver NPs (13, 41.9.0%). This review study highlighted the high anti-gastric cancer potential of a wide range of organic and non-organic NPs through their activity via some mechanisms, such as the induction of apoptosis, gene therapy, and drug delivery. Nonetheless, further studies, especially in clinical settings, are needed to confirm their anti-gastric effects and accurate mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Threshold-awareness in adaptive cancer therapy.
- Author
-
Wang, MingYi, Scott, Jacob G., and Vladimirsky, Alexander
- Subjects
CANCER treatment ,STOCHASTIC control theory ,DYNAMIC programming ,BUDGET ,QUALITY of life - Abstract
Although adaptive cancer therapy shows promise in integrating evolutionary dynamics into treatment scheduling, the stochastic nature of cancer evolution has seldom been taken into account. Various sources of random perturbations can impact the evolution of heterogeneous tumors, making performance metrics of any treatment policy random as well. In this paper, we propose an efficient method for selecting optimal adaptive treatment policies under randomly evolving tumor dynamics. The goal is to improve the cumulative "cost" of treatment, a combination of the total amount of drugs used and the total treatment time. As this cost also becomes random in any stochastic setting, we maximize the probability of reaching the treatment goals (tumor stabilization or eradication) without exceeding a pre-specified cost threshold (or a "budget"). We use a novel Stochastic Optimal Control formulation and Dynamic Programming to find such "threshold-aware" optimal treatment policies. Our approach enables an efficient algorithm to compute these policies for a range of threshold values simultaneously. Compared to treatment plans shown to be optimal in a deterministic setting, the new "threshold-aware" policies significantly improve the chances of the therapy succeeding under the budget, which is correlated with a lower general drug usage. We illustrate this method using two specific examples, but our approach is far more general and provides a new tool for optimizing adaptive therapies based on a broad range of stochastic cancer models. Author summary: Tumor heterogeneities provide an opportunity to improve therapies by leveraging complex (often competitive) interactions of different types of cancer cells. These interactions are usually stochastic due to both individual cell differences and random events affecting the patient as a whole. The new generation of cancer models strive to account for this inherent stochasticity, and adaptive treatment plans need to reflect it as well. In optimizing such treatment, the most common approach is to maximize the probability of eventually stabilizing or eradicating the tumor. In this paper, we consider a more nuanced version of success, maximizing the probability of reaching these therapy goals before the cumulative burden from the disease and treatment exceed a chosen threshold. Importantly, our method allows computing such optimal treatment plans efficiently and for a range of thresholds at once. If used on a high-fidelity personalized model, our general approach could potentially be used by clinicians to choose the most suitable threshold after a detailed discussion of a specific patient's goals (e.g., to include the trade-offs between toxicity and quality of life). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?
- Author
-
Fengqin Liu, Xia Miao, Lu Han, and Xiao Song
- Subjects
LUNG cancer ,CELLULAR therapy ,CYTOKINE release syndrome ,CANCER treatment ,CHIMERIC antigen receptors - Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide necessitating the development of innovative therapeutic strategies. Chimeric antigen receptor (CAR) natural killer (NK) cell therapy represents a promising advancement in the field of oncology offering a novel approach to target and eliminate tumor cells with high specificity and reduced risk of immune-related adverse effects. This paper reviews the mechanism, potential targets, and recent advances in CAR-NK cell therapy for lung cancer, including the design and engineering of CAR-NK cells, preclinical studies, and the outcomes of early-phase clinical trials. We highlight the unique advantages of using NK cells, such as their innate ability to recognize and kill cancer cells and their reduced potential for inducing graft-versus-host disease (GvHD) and cytokine release syndrome (CRS) compared to CAR T-cell therapies. Results from recent studies demonstrate significant antitumor activity in lung cancer models with improved targeting and persistence of CAR-NK cells observed in vitro and in vivo. Finally, we discuss the challenges in optimizing CAR-NK cell therapies, including the potential resistance mechanisms. The paper concludes with an outlook on the future directions of CAR-NK cell research and its implications for lung cancer treatment emphasizing the importance of continued innovation and collaboration in the field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Tumor Treating Fields: Modeling and a numerical algorithm.
- Author
-
Shen, Jun, Gong, Rongfang, Chen, Chunxiao, Wang, Liang, Lin, Zhe, Lo, Catharine W. K., and Lu, Ming
- Subjects
ELECTRIC field therapy ,PARTICLE swarm optimization ,ALGORITHMS ,CANCER treatment - Abstract
This paper investigates the optimal control problem generated in Tumor Treating Fields (TTFields). TTFields is an emerging cancer treatment method with several advantages including the convenience of treatment, fewer side effects, and a better quality of life for patients. Therefore, it holds significant promise for applications in cancer treatments and other fields. In view of such an immense potential, in this work, we are motivated to determine the optimal arrangement of electrodes for TTFields. The paper begins by presenting a comprehensive modeling process for TTFields, followed by the establishment of an optimal control problem that involves finding the optimal configuration of the electrode array. To solve this problem, the particle swarm optimization (PSO) algorithm, which is a type of intelligent algorithm, is employed, and is further improved on to address various situations. Finally, the model is validated and the effectiveness of the PSO algorithm is verified through numerical examples. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Chemotherapy Regimen Optimization Using a Two-Archive Multi-Objective Squirrel Search Algorithm.
- Author
-
Huo, Lin, Liang, Xi, and Huo, Donglin
- Subjects
CANCER chemotherapy ,COMBINATION drug therapy ,SEARCH algorithms ,TUMOR growth ,DRUG resistance ,CANCER treatment - Abstract
Chemotherapy is one of the most effective treatments for cancer, but the efficacy of standard chemotherapy regimens is often limited by toxicities and the individual heterogeneity of cancers. Precise dosing is an important tool to improve efficacy and reduce significant differences in toxicity. However, most of the existing studies on chemotherapy optimization fail to fully consider the toxic side effects, drug resistance, and drug combinations, and thus the chemotherapy regimens obtained may face difficulty in achieving the expected efficacy and also affect the subsequent treatment. Therefore, this paper establishes a tumor growth model for the combination chemotherapy of cell cycle-specific and non-cycle-specific drugs and includes the factors of acquired drug resistance and toxic side effects, proposing an improved multi-objective Squirrel Search Algorithm, the TA-MOSSA, to solve the problem of accurate chemotherapy drug optimization. In this paper, experiments were conducted to analyze the efficacy of chemotherapy dosing regimens obtained by the TA-MOSSA based on the tumor growth model, and the results show that the TA-MOSSA can provide effective chemotherapy regimens for patients who take different treatment approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Deep Segmentation Techniques for Breast Cancer Diagnosis.
- Author
-
Schutte, Storm and Uddin, Jia
- Subjects
BREAST cancer diagnosis ,DIAGNOSTIC imaging ,DEEP learning ,PATHOLOGY ,CANCER treatment - Abstract
Background: This research goes into in deep learning technologies within the realm of medical imaging, with a specific focus on the detection of anomalies in medical pathology, emphasizing breast cancer. It underscores the critical importance of segmentation techniques in identifying diseases and addresses the challenges of scarce labelled data in Whole Slide Images. Additionally, the paper provides a review, cataloguing 61 deep learning architectures identified during the study. Objectives: The aim of this study is to present and assess a novel quantitative approach utilizing specific deep learning architectures, namely the Feature Pyramid Net-work and the Linknet model, both of which integrate a ResNet34 layer encoder to enhance performance. The paper also seeks to examine the efficiency of a semi-supervised training regimen using a dual model architecture, consisting of 'Teacher' and 'Student' models, in addressing the issue of limited labelled datasets. Methods: Employing a semi-supervised training methodology, this research enables the 'Student' model to learn from the 'Teacher' model's outputs. The study methodically evaluates the models' stability, accuracy, and segmentation capabilities, employing metrics such as the Dice Coefficient and the Jaccard Index for comprehensive assessment. Results: The investigation reveals that the Linknet model exhibits good performance, achieving an accuracy rate of 94% in the detection of breast cancer tissues utilizing a 21-seed parameter for the initialization of model weights. It further excels in generating annotations for the 'Student' model, which then achieves a 91% accuracy with minimal computational demands. Conversely, the Feature Pyramid Network model demonstrates a slightly lower accuracy of 93% in the Teacher model but exhibits improved and more consistent results in the 'Student' model, reaching 95% accuracy with a 42-seed parameter. Conclusions: This study underscores the efficacy and potential of the Feature Pyra-mid Network and Linknet models in the domain of medical image analysis, particularly in the detection of breast cancer, and suggests their broader applicability in various medical segmentation tasks related to other pathology disorders. Furthermore, the research enhances the understanding of the pivotal role that deep learning technologies play in advancing diagnostic methods within the field of medical imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Examining structural factors influencing cancer care experienced by Inuit in Canada: a scoping review.
- Author
-
Huang, Wen Qiu, Gifford, Wendy, Phillips, J. Craig, and Coburn, Veldon
- Subjects
CANADIAN Inuit ,CANCER treatment ,CANADIANS ,GREY literature ,INUIT - Abstract
Inuit face worse cancer survival rates and outcomes than the general Canadian population. Persistent health disparities cannot be understood without examining the structural factors that create inequities and continue to impact the health and well-being of Inuit. This scoping review aims to synthesise the available published and grey literature on the structural factors that influence cancer care experienced by Inuit in Canada. Guided by Inuit input from Pauktuutit Inuit Women of Canada as well as the Joanna Briggs Institute scoping review methodology, a comprehensive electronic search along with hand-searching of grey literature and relevant journals was conducted. A total of 30 papers were included for analysis and assessment of relevance. Findings were organised into five categories as defined in the a priori framework related to colonisation, as well as health systems, social, economic, and political structures. The study results highlight interconnections between racism and colonialism, the lack of health service information on urban Inuit, as well as the need for system-wide efforts to address the structural barriers in cancer care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. What Is a Sarcoma 'Specialist Center'? Multidisciplinary Research Finds an Answer.
- Author
-
Wilson, Roger, Reinke, Denise, van Oortmerssen, Gerard, Gonzato, Ornella, Ott, Gabriele, Raut, Chandrajit P., Guadagnolo, B. Ashleigh, Haas, Rick L. M., Trent, Jonathan, Jones, Robin, Pretorius, Lauren, Felser, Brandi, Basson, Mandy, Schuster, Kathrin, and Kasper, Bernd
- Subjects
CANCER treatment ,SARCOMA ,MEDICAL specialties & specialists ,MEDICAL quality control ,MEDICAL care ,PATIENT advocacy ,BUSINESS networks ,INTERDISCIPLINARY research ,QUALITY assurance ,SPECIALTY hospitals ,HEALTH care teams - Abstract
Simple Summary: A multidisciplinary group researched and defined criteria to describe a sarcoma specialist treatment center or network. The project is led by Sarcoma Patient Advocacy Global Network (SPAGN), involves patient groups from around the world and is supported by clinical specialists and leading researchers. The paper identifies Core Principles and Key Features which define a specialist center/network. They are supported by evidence and experience. A primary aim is that new patients and their families can identify a specialist center which can provide curative treatment. A secondary aim is that countries where specialist treatment is not yet available can identify what they have to achieve to meet that ambition. The Core Principles allow a center or network to attain accreditation as a Sarcoma Intelligent Specialist Network. The Key Features are more aspirational and are expressed in a way that allows local needs, legal considerations and budgetary pressures to be taken into account. This is the first time an expert multidisciplinary group has defined specialism in cancer treatment in a worldwide context. The management of sarcomas in specialist centers delivers significant benefits. In much of the world, specialists are not available, and the development of expertise is identified as a major need. However, the terms 'specialist' or 'expert' center are rarely defined. Our objective is to offer a definition for patient advocates and a tool for healthcare providers to underpin improving the care of people with sarcoma. SPAGN developed a discussion paper for a workshop at the SPAGN 2023 Conference, attended by 75 delegates. A presentation to the Connective Tissue Oncology Society (CTOS) and further discussion led to this paper. Core Principles were identified that underlie specialist sarcoma care. The primary Principle is the multi-disciplinary team discussing every patient, at first diagnosis and during treatment. Principles for optimal sarcoma management include accurate diagnosis followed by safe, high-quality treatment, with curative intent. These Principles are supplemented by Features describing areas of healthcare, professional involvement, and service provision and identifying further research and development needs. These allow for variations because of national or local policies and budgets. We propose the term 'Sarcoma Intelligent Specialist Network' to recognize expertise wherever it is found in the world. This provides a base for further discussion and local refinement. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Twin studies as an innovative approach to address research questions in cancer care within primary care settings.
- Author
-
Sahu, Monalisha
- Subjects
TWIN studies ,RESEARCH questions ,PRIMARY care ,DIZYGOTIC twins ,CANCER treatment ,SPERM banks - Abstract
This paper proposes the utilisation of twin studies as a novel and powerful methodological approach to investigate critical research questions pertaining to cancer prevention, screening, diagnosis, treatment and survivorship within primary care contexts. The inherent genetic similarity between monozygotic (MZ) (identical) twins provides a unique opportunity to disentangle genetic and environmental influences on cancer-related outcomes. MZ twins share virtually identical genetic makeup, offering a unique opportunity to discern the relative contributions of genetic and environmental factors to cancer-related outcomes. In contrast, dizygotic (DZ) twins, also known as fraternal twins, develop from two separate eggs fertilised by two different sperm and share on average 50% of their genetic material, the same level of genetic similarity found in non-twin siblings. Comparisons between MZ and DZ twins enable researchers to disentangle hereditary factors from shared environmental influences. This methodology has the potential to advance our understanding of the multifaceted interplay between genetic predisposition, lifestyle factors and healthcare interventions in the context of cancer care. This paper outlines the rationale, design considerations and potential applications of twin studies in primary care-based cancer research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy.
- Author
-
Chen, Huanxiang, Liu, Hongyang, Zhang, Chenxing, Xiao, Nan, Li, Yang, Zhao, Xiangzhuan, Zhang, Ruike, Gu, Huihui, Kang, Qiaozhen, and Wan, Junhu
- Subjects
RNA modification & restriction ,RNA methylation ,CANCER cell migration ,CANCER treatment ,RNA - Abstract
RNA methylation is widespread in nature. Abnormal expression of proteins associated with RNA methylation is strongly associated with a number of human diseases including cancer. Increasing evidence suggests that targeting RNA methylation holds promise for cancer treatment. This review specifically describes several common RNA modifications, such as the relatively well‐studied N6‐methyladenosine, as well as 5‐methylcytosine and pseudouridine (Ψ). The regulatory factors involved in these modifications and their roles in RNA are also comprehensively discussed. We summarise the diverse regulatory functions of these modifications across different types of RNAs. Furthermore, we elucidate the structural characteristics of these modifications along with the development of specific inhibitors targeting them. Additionally, recent advancements in small molecule inhibitors targeting RNA modifications are presented to underscore their immense potential and clinical significance in enhancing therapeutic efficacy against cancer. Key Points: In this paper, several important types of RNA modifications and their related regulatory factors are systematically summarised.Several regulatory factors related to RNA modification types were associated with cancer progression, and their relationships with cancer cell migration, invasion, drug resistance and immune environment were summarised.In this paper, the inhibitors targeting different regulators that have been proposed in recent studies are summarised in detail, which is of great significance for the development of RNA modification regulators and cancer treatment in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Ianus Bifrons : The Two Faces of Metformin.
- Author
-
Goglia, Umberto, Hasballa, Iderina, Teti, Claudia, Boschetti, Mara, Ferone, Diego, and Albertelli, Manuela
- Subjects
THERAPEUTIC use of antineoplastic agents ,METFORMIN ,ADIPOSE tissues ,GLYCEMIC control ,CELLULAR signal transduction ,INSULIN resistance ,BLOOD sugar ,MOLECULAR structure ,CELL survival ,TUMORS ,DIABETES ,OBESITY ,PHARMACODYNAMICS - Abstract
Simple Summary: Metformin is one of the most widely used drugs in the world, since its first use in the second part of the 1950s in France (Aron, 1957) and in the United Kingdom (Rona, 1958), and is on the World Health Organization's List of Essential Medicines. Traditionally, metformin is used in diabetes mellitus, mainly in overweight and obese subjects, but also in other conditions of impaired glucose metabolism, such as insulin resistance. In recent years, in vitro and in vivo data on this molecule as an antiproliferative modulator have suggested a series of clinical trials in several tumors that—at the moment—have not confirmed the expected positive results. The aim of this paper is to offer a double vision of this molecule, with a very light side about the metabolic aspects and a darker side concerning its antineoplastic activity, focusing on molecular and subcellular pathways involved in both fields and discussing the contrast between preliminary cellular data and real clinical outcomes in different neoplasms. The ancient Roman god Ianus was a mysterious divinity with two opposite faces, one looking at the past and the other looking to the future. Likewise, metformin is an "old" drug, with one side looking at the metabolic role and the other looking at the anti-proliferative mechanism; therefore, it represents a typical and ideal bridge between diabetes and cancer. Metformin (1,1-dimethylbiguanidine hydrochloride) is a drug that has long been in use for the treatment of type 2 diabetes mellitus, but recently evidence is growing about its potential use in other metabolic conditions and in proliferative-associated diseases. The aim of this paper is to retrace, from a historical perspective, the knowledge of this molecule, shedding light on the subcellular mechanisms of action involved in metabolism as well as cellular and tissue growth. The intra-tumoral pharmacodynamic effects of metformin and its possible role in the management of different neoplasms are evaluated and debated. The etymology of the name Ianus is probably from the Latin term ianua, which means door. How many new doors will this old drug be able to open? [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Editorial: Evolution of phytochemicals and phytotherapies in the treatment and management of cancer: targeted strategies in cancer precision medicine.
- Author
-
Adnan, Mohd, Pasupuleti, Visweswara Rao, and Patel, Mitesh
- Subjects
INDIVIDUALIZED medicine ,CANCER treatment ,PHYTOCHEMICALS ,PRECISION farming ,NATURAL products - Published
- 2023
- Full Text
- View/download PDF
27. Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis.
- Author
-
Bo Song, Zheyu Lin, Chuyao Feng, Xu Zhao, and Weiping Teng
- Subjects
BIBLIOMETRICS ,THYROID cancer ,CANCER treatment ,IODINE isotopes ,MEDICAL technology ,WATCHFUL waiting - Abstract
Background: Papillary thyroid cancer (PTC) is the most common endocrine malignancy worldwide. The treatment of PTC has attracted extensive attention and discussion from the public and scholars. However, no article has systematically assessed the related literature. Therefore, we conducted a bibliometric and knowledge map analysis to reveal the dynamic scientific developments in the PTC therapy field. Methods: We retrieved publications related to PTC therapy from the Web of Scientific Core Collection (WoSCC) on May 1, 2023. The bibliometric package in R software, VOSviewer and CiteSpace software were used to analyze countries/ regions, institutions, journals, authors, references, and keywords. Then, we systematized and summarized the research landscape, global trends and hot topics of research. Results: This bibliometric analysis spanned from 2012 to 2022 and involved 18,501 authors affiliated with 3,426 institutions across 87 countries/regions, resulting in the publication of 3,954 papers in 860 academic journals. Notably, the number of publications and citations related to PTC therapy research has exhibited a steady increase over the past decade. China and the United States have emerged as leading contributors in terms of publication count, with the United States also being the most cited country. Furthermore, among the top 10 institutions with the highest number of published papers, half were located in China. Among the journals, Thyroid is ranked first in terms of total publications and citations. The most productive individual author was Miyauchi Akira. While previous research primarily focused on surgery and radioactive iodine therapy, the increasing emphasis on health awareness and advancements in medical technology have led to the emergence of active surveillance, thermal ablation, and genomic analysis as prominent areas of research. Conclusion: In conclusion, this comprehensive and quantitative bibliometric analysis elucidates the research trends and hotspots within PTC therapy, drawing rom a substantial body of publications. This study provides valuable insights into the historical and current landscape of PTC therapy research while also offering guidance for future research directions. This study serves as a valuable resource for researchers and practitioners seeking new avenues of exploration in the field. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review.
- Author
-
Taylor, Sally, Law, Kate, Coomber-Moore, Jake, Davies, Michelle, Thistlewaite, Fiona, Calvert, Mel, Aiyegbusi, Olalekan, and Yorke, Janelle
- Subjects
CELLULAR therapy ,PATIENT reported outcome measures ,CANCER treatment ,CINAHL database ,FOLLOW-up studies (Medicine) - Abstract
Introduction: Adoptive cell therapy (ACT) is a rapidly evolving field. Patient-reported outcomes (PROs) allow patients to report the impact of treatment on their quality of life during and after treatment. The systematic review aims to characterise the breadth of PROs utilised in ACT cancer care and provide guidance for the use of PROs in this patient population in the future. Methods: A systematic search was conducted (MEDLINE, PsycINFO, Embase and CINAHL) in August 2021 by two reviewers. Search terms covered the following: "adoptive cell therapy", "patient-reported outcomes" and "cancer". Studies were included if they used a PRO measure to report the impact of ACT. The methodological quality of PROs was assessed. Forward and backward reference searching was conducted of any relevant papers. A quality grading scale was applied based on Cochrane and Revenson criteria for classification of high-quality studies. Key data from the studies and the included PROs was extracted by two researchers and tabulated. Results: One-hundred nine papers were identified; 11 papers were included. The majority of studies were single-arm trials or observational studies. Twenty-two different PROs were identified; none was ACT specific. The PROMIS-29 and EQ-5D were most commonly used. Few studies collected PRO data in the first 1–2 weeks. Four studies followed patients up for over a year, and a further four studies followed patients for approximately 3 months. Discussion: None of the PROs identified have been designed specifically for ACT. Appropriateness of existing instruments should be considered. It should be considered whether it is appropriate to collect data more frequently in the acute stage and then less frequently during follow-up. It should be considered if one tool is suitable at all time points or if the tool should be adapted depending on time since treatment. More research is needed to identify the exact timings of PRO assessments, and qualitative work with patients is needed to determine the most important issues for them throughout the treatment and follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Real-World Cost-Effectiveness Analysis: How Much Uncertainty Is in the Results?
- Author
-
Barr, Heather K., Guggenbickler, Andrea M., Hoch, Jeffrey S., and Dewa, Carolyn S.
- Subjects
CANCER treatment ,COST effectiveness ,CANCER ,MEDICAL care ,WILLINGNESS to pay - Abstract
Cost-effectiveness analyses of new cancer treatments in real-world settings (e.g., post-clinical trials) inform healthcare decision makers about their healthcare investments for patient populations. The results of these analyses are often, though not always, presented with statistical uncertainty. This paper identifies five ways to characterize statistical uncertainty: (1) a 95% confidence interval (CI) for the incremental cost-effectiveness ratio (ICER); (2) a 95% CI for the incremental net benefit (INB); (3) an INB by willingness-to-pay (WTP) plot; (4) a cost-effectiveness acceptability curve (CEAC); and (5) a cost-effectiveness scatterplot. It also explores their usage in 22 articles previously identified by a rapid review of real-world cost effectiveness of novel cancer treatments. Seventy-seven percent of these articles presented uncertainty results. The majority those papers (59%) used administrative data to inform their analyses while the remaining were conducted using models. Cost-effectiveness scatterplots were the most commonly used method (34.3%), with 40% indicating high levels of statistical uncertainty, suggesting the possibility of a qualitatively different result from the estimate given. Understanding the necessity for and the meaning of uncertainty in real-world cost-effectiveness analysis will strengthen knowledge translation efforts to improve patient outcomes in an efficient manner. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. DNA Damage Repair Defects and Targeted Radionuclide Therapies for Prostate Cancer: Does Mutation Really Matter? A Systematic Review.
- Author
-
Filippi, Luca, Palumbo, Barbara, Bagni, Oreste, Frantellizzi, Viviana, De Vincentis, Giuseppe, and Schillaci, Orazio
- Subjects
DNA repair ,DNA damage ,PROSTATE cancer ,RADIOISOTOPES ,PROGRESSION-free survival ,RADIONUCLIDE imaging ,CANCER treatment - Abstract
The aim of the present review was to assess the impact of DNA damage repair (DDR) mutations on response and outcome of patients (pts) affected by advanced prostate cancer (PCa) submitted to radionuclide therapies with [
223 Ra]RaCl2 (223 Ra-therapy) or prostate specific membrane antigen (PSMA) ligands. A systematic literature search according to PRISMA criteria was made by using two main databases. Only studies published up until to October 2022 in the English language with ≥10 enrolled patients were selected. Seven studies including 326 pts, of whom 201 (61.6%) harboring DDR defects, were selected. The majority of selected papers were retrospective and four out of seven (57.1%) had small sample size (<50 pts). Three out of seven (42.8%) studies reported a more favorable outcome (overall or progression free survival) after therapy with alpha emitters (223 Ra-therapy or [225 Ac]Ac-PSMA-617) in subjects with DDR defects with respect to those without mutations. In two studies employing alpha or beta emitters ([177 Lu]/[225 Ac]-PMSA), no significant benefit was registered in pts harboring DDR defects. In all but one paper, no significant difference in response rate was reported among pts with or without DDR mutations. Although preliminary and biased by the retrospective design, preliminary data suggest a trend towards a longer survival in PCa pts harboring DDR defects submitted to radionuclide targeted therapy with alpha emitters. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
31. Specifically designed diets demonstrate a "powerful ability" to prevent tumorigenesis, delay tumor growth and improve existing cancer treatments, CNIO researchers say in a review paper.
- Subjects
TUMOR growth ,CANCER treatment ,DIET ,NEOPLASTIC cell transformation ,TRANSFORMING growth factors - Abstract
Interaction with the immune system One of the main factors responsible for tumor growth, and for therapeutic success, is the interaction between tumor cells and the patient's immunity. Keywords: Cancer; Centro Nacional de Investigaciones Oncologicas (CNIO); Clinical Research; Clinical Trials and Studies; Diet and Nutrition; Drugs and Therapies; Health and Medicine; Inflammation; Ketogenic Diet; Oncology; Pre-Trial Research EN Cancer Centro Nacional de Investigaciones Oncologicas (CNIO) Clinical Research Clinical Trials and Studies Diet and Nutrition Drugs and Therapies Health and Medicine Inflammation Ketogenic Diet Oncology Pre-Trial Research 1165 1165 1 06/12/23 20230613 NES 230613 2023 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Diet influences the incidence, growth and progression of cancer, to the extent that one-third of the most common cancers can be prevented, at least in part, by dietary changes. [Extracted from the article]
- Published
- 2023
32. Services, models of care, and interventions to improve access to cancer treatment for adults who are socially disadvantaged: A scoping review protocol.
- Author
-
Horrill, Tara C., Bourgeois, Amber, Kleijberg, Max, Linton, Janice, Leahy, Kate, and Stajduhar, Kelli I.
- Subjects
SOCIAL marginality ,CANCER treatment ,CANCER patients ,ACADEMIC librarians ,SOCIAL determinants of health - Abstract
Timely access to guideline-recommended cancer treatment is known to be an indicator of the quality and accessibility of a cancer care system. Yet people who are socially disadvantaged experience inequities in access to cancer treatment that have significant impacts on cancer outcomes and quality of life. Among people experiencing the intersecting impacts of poor access to the social determinants of health and personal identities typically marginalized from society ('social disadvantage'), there are significant barriers to accessing cancer, many of which compound one another, making cancer treatment extremely difficult to access. Although some research has focused on barriers to accessing cancer treatment among people who are socially disadvantaged, it is not entirely clear what, if anything, is being done to mitigate these barriers and improve access to care. Increasingly, there is a need to design cancer treatment services and models of care that are flexible, tailored to meet the needs of patients, and innovative in reaching out to socially disadvantaged groups. In this paper, we report the protocol for a planned scoping review which aims to answer the following question: What services, models of care, or interventions have been developed to improve access to or receipt of cancer treatment for adults who are socially disadvantaged? Based on the methodological framework of Arksey and O'Malley, this scoping review is planned in six iterative stages. A comprehensive search strategy will be developed by an academic librarian. OVID Medline, EMBASE, CINAHL (using EBSCOhost) and Scopus will be searched for peer-reviewed published literature; advanced searches in Google will be done to identify relevant online grey literature reports. Descriptive and thematic analysis methods will be used to analyze extracted data. Findings will provide a better understanding of the range and nature of strategies developed to mitigate barriers to accessing cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Graphene Oxide (GO) for the Treatment of Bone Cancer: A Systematic Review and Bibliometric Analysis.
- Author
-
Barba-Rosado, Lemy Vanessa, Carrascal-Hernández, Domingo César, Insuasty, Daniel, and Grande-Tovar, Carlos David
- Subjects
BIBLIOMETRICS ,BONE cancer ,CANCER treatment ,THERAPEUTICS ,PHOTODYNAMIC therapy ,NANOCARRIERS - Abstract
Cancer is a severe disease that, in 2022, caused more than 9.89 million deaths worldwide. One worrisome type of cancer is bone cancer, such as osteosarcoma and Ewing tumors, which occur more frequently in infants. This study shows an active interest in the use of graphene oxide and its derivatives in therapy against bone cancer. We present a systematic review analyzing the current state of the art related to the use of GO in treating osteosarcoma, through evaluating the existing literature. In this sense, studies focused on GO-based nanomaterials for potential applications against osteosarcoma were reviewed, which has revealed that there is an excellent trend toward the use of GO-based nanomaterials, based on their thermal and anti-cancer activities, for the treatment of osteosarcoma through various therapeutic approaches. However, more research is needed to develop highly efficient localized therapies. It is suggested, therefore, that photodynamic therapy, photothermal therapy, and the use of nanocarriers should be considered as non-invasive, more specific, and efficient alternatives in the treatment of osteosarcoma. These options present promising approaches to enhance the effectiveness of therapy while also seeking to reduce side effects and minimize the damage to surrounding healthy tissues. The bibliometric analysis of photothermal and photochemical treatments of graphene oxide and reduced graphene oxide from January 2004 to December 2022 extracted 948 documents with its search strategy, mainly related to research papers, review papers, and conference papers, demonstrating a high-impact field supported by the need for more selective and efficient bone cancer therapies. The central countries leading the research are the United States, Iran, Italy, Germany, China, South Korea, and Australia, with strong collaborations worldwide. At the same time, the most-cited papers were published in journals with impact factors of more than 6.0 (2021), with more than 290 citations. Additionally, the journals that published the most on the topic are high impact factor journals, according to the analysis performed, demonstrating the high impact of the research field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan
- Author
-
Ingrid Nyhus Moen, Hanne Hella, Kristine Misund, Tobias S. Slørdahl, Erling Håland, Elias Veidal, and Kristian K. Starheim
- Subjects
Melphalan ,MAPK/ERK pathway ,Programmed cell death ,Kinase ,Chemistry ,TAK1 ,apoptosis ,MAP3K7 ,medicine.disease ,NF-κB ,cancer treatment ,multiple myeloma ,Oncology ,Cancer research ,medicine ,Cytotoxic T cell ,Protein kinase A ,Multiple myeloma ,medicine.drug ,Research Paper - Abstract
Multiple myeloma (MM) is an incurable cancer caused by malignant transformation of plasma cells. Transforming growth factor-β activated kinase 1 (MAP3K7, TAK1) is a major regulator of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) signaling. Both NF-κB and MAPK control expression of genes with vital roles for drug resistance in MM. TAK1 is an attractive drug target as it switches these survival pathways to cell death. Our analysis showed that patients with high MAP3K7 expression in the tumor had shorter overall and progression free survival. The TAK1-inhibitors NG25 and 5Z-7-oxozeaenol (5Z-7) were cytotoxic to MM cell lines and patient cells. NG25 reduced expression of MYC and E2F controlled genes, involved in tumor cell growth, cell cycle progression and drug resilience. TAK1 can be activated by genotoxic stress. NG25 and 5Z-7 induced both synergistic and additive cytotoxicity in combination with the alkylating agent melphalan. Melphalan activated TAK1, NF-κB, and the MAPKs p38 and c-Jun N-terminal kinase (JNK), as well as a transcriptional UV-response. This was blocked by NG25, and instead apoptosis was activated. MM induce elevated bone-degradation resulting in myeloma bone disease (MBD), which is the main cause of disability and morbidity in MM patients. NG25 and 5Z-7 reduced differentiation and viability of human bone degrading osteoclasts, suggesting that TAK1-inhibition can have a double beneficial effect for patients. In sum, TAK1 is a promising drug target for MM treatment.
- Published
- 2021
35. Recent advances and prospects of metal–organic frameworks in cancer therapies.
- Author
-
Luo, Zhiying, Sheng, Yu, Jiang, Chenyi, Pan, Ying, Wang, Xiaoxiong, Nezamzadeh-Ejhieh, Ali, Ouyang, Jie, Lu, Chengyu, and Liu, Jianqiang
- Subjects
METAL-organic frameworks ,CANCER treatment ,PHOTODYNAMIC therapy ,THERAPEUTICS ,BREAST cancer - Abstract
Metal–organic frameworks (MOFs) have been broadly applied in biomedical and other fields. MOFs have high porosity, a large comparative area, and good biostability and have attracted significant attention, especially in cancer therapies. This paper presents the latest applications of MOFs in chemodynamic therapy (CDT), sonodynamic therapy (SDT), photodynamic therapy (PDT), photothermal therapy (PTT), immunotherapy (IT), and combination therapy for breast cancer. A combination therapy is the combination of two different treatment modalities, such as CDT and PDT combination therapy, and is considered more effective than separate therapies. Herein, we have also discussed the advantages and disadvantages of combination therapy in the treatment of breast cancer. This paper aims to illustrate the potential of MOFs in new cancer therapeutic approaches, discuss their potential advantages, and provide some reflections on the latest research results. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Advance in Targeted Cancer Therapy and Mechanisms of Resistance.
- Author
-
Tang, Patrick Ming-Kuen and Zhang, Dongmei
- Subjects
CANCER treatment ,CANCER prognosis ,DRUG resistance ,TREATMENT effectiveness ,CANCER invasiveness - Abstract
This document is an editorial from the International Journal of Molecular Sciences discussing the advances in targeted cancer therapy and mechanisms of resistance. The article highlights that drug resistance is a significant clinical challenge in cancer treatment and is caused by the genetic heterogeneity of cancer cells. The tumor microenvironment and immune response also play a critical role in cancer progression and resistance to immunotherapy. The editorial presents a special issue featuring 13 papers that cover various aspects of clinical discovery, resistance mechanisms, and novel therapeutics in cancer treatment. The aim is to inspire researchers to develop effective solutions to overcome drug resistance and improve clinical outcomes for cancer patients. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
37. Worldwide Productivity and Research Trend of Publications Concerning Cancer-Related Neuropathic Pain: A Bibliometric Study.
- Author
-
Yang, Shengjie, Tan, Weijuan, Ma, Xiao, Qi, Lu, and Wang, Xinghe
- Subjects
NEURALGIA ,CANCER pain ,BIBLIOMETRICS ,PUBLISHED articles ,CARCINOGENESIS ,CANCER treatment - Abstract
Cancer-related neuropathic pain is a common adverse effect in the process of cancer development and treatment and has gradually attracted the attention of researchers. The purpose of this article is to systematically review the articles on cancer-related neuropathic pain published between 2012 and 2021 and visualize the data through CiteSpace and R software. The results show that in the past 10 years, a total of 5715 articles have been published, involving 118 categories, of which the most is Clinical Neurology, followed by Neurosciences, Pharmacology Pharmacy. The country with the most published articles is the United States, followed by China and Italy. A total of 22,228 authors were involved in the study of cancer-related neuropathic pain. These historical opinions about cancer-related neuropathic pain could be an important practical basis for further research into potential development trends. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. Non-invasive technology to assess hydration status in advanced cancer to explore relationships between fluid status and symptoms: an observational study using bioelectrical impedance analysis.
- Author
-
Nwosu, Amara Callistus, Stanley, Sarah, Mayland, Catriona R, Mason, Stephen, McDougall, Alexandra, and Ellershaw, John E
- Subjects
STATISTICAL models ,DRINKING (Physiology) ,CANCER treatment ,MEDICAL technology ,RESEARCH funding ,SCIENTIFIC observation ,PILOT projects ,BODY composition ,MEDICAL care ,BIOELECTRIC impedance ,DECISION making ,CANCER patients ,DESCRIPTIVE statistics ,EVALUATION of medical care ,HYDRATION ,LONGITUDINAL method ,WATER in the body ,QUALITY of life ,TUMOR classification ,TUMORS ,TERMINAL care ,COMPARATIVE studies ,DEHYDRATION ,REGRESSION analysis ,SPECIALTY hospitals ,DISEASE complications - Abstract
Background: Oral fluid intake decreases in advanced cancer in the dying phase of illness. There is inadequate evidence to support the assessment, and management, of hydration in the dying. Bioelectrical impedance analysis (BIA) is a body composition assessment tool. BIA has the potential to inform clinal management in advanced cancer, by examining the relationships between hydration status and clinical variables. Aim: BIA was used to determine the association between hydration status, symptoms, clinical signs, quality-of-life and survival in advanced cancer, including those who are dying (i.e. in the last week of life). Materials and methods: We conducted a prospective observational study of people with advanced cancer in three centres. Advance consent methodology was used to conduct hydration assessments in the dying. Total body water was estimated using the BIA Impedance index (Height – H (m)
2 /Resistance – R (Ohms)). Backward regression was used to identify factors (physical signs, symptoms, quality of life) that predicted H2 /R. Participants in the last 7 days of life were further assessed with BIA to assess hydration changes, and its relationship with clinical outcomes. Results: One hundred and twenty-five people participated (males n = 74 (59.2%), females, n = 51 (40.8%)). We used backward regression analysis to describe a statistical model to predict hydration status in advanced cancer. The model demonstrated that 'less hydration' (lower H2 /R) was associated with female sex (Beta = -0.39, p < 0.001), increased appetite (Beta = -0.12, p = 0.09), increased dehydration assessment scale score (dry mouth, dry axilla, sunken eyes - Beta = -0.19, p = 0.006), and increased breathlessness (Beta = -0.15, p = 0.03). 'More hydration' (higher H2 /R) was associated with oedema (Beta = 0.49, p < 0.001). In dying participants (n = 18, 14.4%), hydration status (H2 /R) was not significantly different compared to their baseline measurements (n = 18, M = 49.6, SD = 16.0 vs. M = 51.0, SD = 12.1; t(17) = 0.64, p = 0.53) and was not significantly associated with agitation (rs = -0.85, p = 0.74), pain (rs = 0.31, p = 0.23) or respiratory tract secretions (rs = -0.34, p = 0.19). Conclusions: This is the first study to use bioimpedance to report a model (using clinical factors) to predict hydration status in advanced cancer. Our data demonstrates the feasibility of using an advance consent method to conduct research in dying people. This method can potentially improve the evidence base (and hence, quality of care) for the dying. Future BIA research can involve hydration assessment of cancers (according to type and stage) and associated variables (e.g., stage of illness, ethnicity and gender). Further work can use BIA to identify clinically relevant outcomes for hydration studies and establish a core outcome set to evaluate how hydration affects symptoms and quality-of-life in cancer. Key message: What is already known about this topic? - Oral fluid intake decreases in people with advanced cancer, especially when they approach the dying phase of their illness. - There is inadequate evidence to support hydration assessment and decision making in the dying phase of illness. - It is important to understand which clinical factors are associated with hydration status in advanced cancer, to enable healthcare professionals, to evaluate hydration status and support clinical decision making. - Bioimpedance is a non-invasive technology, which has potential to identify clinically relevant variables for cancer hydration assessment. What this paper adds. - This is the first study to use bioimpedance to report a model (using clinical factors) to predict hydration status in advanced cancer. - The variables with combined significance for predicting hydration status were biological sex, appetite, dry mouth, dry axilla, sunken eyes, breathlessness and oedema. In the dying phase, hydration status did not significantly change compared to baseline, and hydration status was not significantly associated with survival. Implications for practice, theory or policy. - Further work can use bioimpedance to identify clinically relevant outcomes for hydration studies, to establish a core outcome set to evaluate how hydration affects symptoms and quality-of-life in cancer. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
39. Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.
- Author
-
Hirose, Takeshi, Ito, Mamoru, Tsuchihashi, Kenji, Ozaki, Yukinori, Nishio, Hiroshi, Ichihara, Eiki, Miura, Yuji, Yano, Shingo, Maruyama, Dai, Yoshinami, Tetsuhiro, Susumu, Nobuyuki, Takekuma, Munetaka, Motohashi, Takashi, Baba, Eishi, Ochi, Nobuaki, Kubo, Toshio, Uchino, Keita, Kimura, Takahiro, Kamiyama, Yutaro, and Nakao, Shinji
- Subjects
- *
EWING'S sarcoma , *CANCER treatment , *FEBRILE neutropenia , *GRANULOCYTE-colony stimulating factor , *PREVENTIVE medicine - Abstract
Background: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?". Methods: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019. Two reviewers assessed the extracted papers and analyzed overall survival (OS), febrile neutropenia (FN) incidence, infection-related mortality, quality of life (QOL), and pain. Results: Twenty-five English and five Japanese articles were identified for CQ #1. After screening, a cohort study of vincristine, ifosfamide, doxorubicin, and etoposide chemotherapy with 851 patients was selected. Incidence of FN was 60.8% with G-CSF and 65.8% without; statistical tests were not conducted. Data on OS, infection-related mortality, QOL, or pain was unavailable. Consequently, CQ #1 was redefined as a future research question. As for CQ #2, we found two English and five Japanese papers, of which one high-quality randomized controlled trial on G-CSF use in intensified chemotherapy was included. This trial showed trends toward lower mortality and a significant increase in event-free survival for 2-week interval regimen with the G-CSF primary prophylactic use compared with 3-week interval. Conclusion: This review indicated that G-CSF's efficacy as primary prophylaxis in Ewing sarcoma, except in children, is uncertain despite its common use. This review tentatively endorses intensified chemotherapy with G-CSF primary prophylaxis for Ewing sarcoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Nanomedicine-induced programmed cell death enhances tumor immunotherapy.
- Author
-
Lu, Jiaye, Tai, Zongguang, Wu, Junchao, Li, Lisha, Zhang, Tingrui, Liu, Jun, Zhu, Quangang, and Chen, Zhongjian
- Subjects
- *
APOPTOSIS , *NANOMEDICINE , *IMMUNOTHERAPY , *TUMOR treatment , *CANCER treatment , *CANCER-related mortality - Abstract
[Display omitted] • This article focuses on immunotherapy, a new treatment for tumors with low side effects, and suggests the direction of improvement. • Programmed cell death (apoptosis, necroptosis, ferroptosis, pyroptosis and autophagy) induced by nanomedicine was reviewed in this paper. • This paper focuses on the role of nanomedicine-induced programmed cell death in cancer therapy. • This article reviews the improvement of the limitations of immunotherapy with nanomedicine-induced PCD. • In this paper, the development prospect of tumor therapy and immunotherapy of PCD mediated by nanomedical drugs is prospected. There has been widespread concern about the high cancer mortality rate and the shortcomings of conventional cancer treatments. Immunotherapy is a novel oncology therapy with high efficiency and low side effects, which is a revolutionary direction for clinical oncology treatment. However, its clinical effectiveness is uneven. Based on the redefinition and reclassification of programmed cell death (PCD) (divided into necroptosis, ferroptosis, pyroptosis, and autophagy), the role of nanomedicine-induced PCD in cancer therapy has also received significant attention. Clinical and preclinical studies have begun to combine PCD with immunotherapy. In this article, we present recent research in tumor immunotherapy, provide an overview of how nanomedicine-induced PCD is involved in tumor therapy, and review how nanomedicine-induced PCD can improve the limitations of immunotherapy to enhance tumor immunotherapy. The future development of nanomedicine-mediated PCD tumor therapy and tumor immunotherapy is also proposed Key scientific concepts of overview Nanomedicine-induced PCD is a prospective method of tumor immunotherapy. Nanomedicines increase tumor site penetration and targeting ability, and nanomedicine-mediated PCD activation can stimulate powerful anti-tumor immune effects, which has a good contribution to immunotherapy of tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Synthesis, characterization, and anti-cancer potential of novel p53-mediated Mdm2 and Pirh2 modulators: an integrated In silico and In vitro approach.
- Author
-
Niazi, Sarfaraj, Kavana, C. P., Aishwarya, H. K., Dharmashekar, Chandan, Jain, Anisha, Wani, Tanveer A., Shivamallu, Chandan, Purohit, Madhusudan N., Kollur, Shiva Prasad, Sekar, Mahendran, and Cui, Wenqiang
- Subjects
LEUKEMIA ,CANCER treatment ,DRUG discovery ,SMALL molecules ,P53 antioncogene - Abstract
Introduction: Leukemia is a global health concern that requires alternative treatments due to the limitations of the FDA-approved drugs. Our focus is on p53, a crucial tumor suppressor that regulates cell division. It appears possible to stabilize p53 without causing damage to DNA by investigating dual-acting inhibitors that target both ligases. The paper aims to identify small molecule modulators of Mdm2 and Pirh2 by using 3D structural models of p53 residues and to further carry out the synthesis and evaluation of hit candidates for anti-cancer potency by in vitro and in silico studies. Methods: We synthesized structural analogues of MMs02943764 and MMs03738126 using a 4,5-(substituted) 1,2,4-triazole-3-thiols with 2-chloro N-phenylacetamide in acetone with derivatives of PAA and PCA were followed. Cytotoxicity assays, including MTT, Trypan Blue Exclusion, and MTS assays, were performed on cancer cell lines. Anti-proliferation activity was evaluated using K562 cells. Cell cycle analysis and protein expression studies of p53, Mdm2, and Pirh2 were conducted using flow cytometry. Results: As for results obtained from our previous studies MMs02943764, and MMs03738126 were selected among the best-fit hit molecules whose structural analogues were further subjected to molecular docking and dynamic simulation. Synthesized compounds exhibited potent anti-proliferative effects, with PAC showing significant cytotoxicity against leukemia cells. PAC induced cell cycle arrest and modulated p53, Mdm2, and Pirh2 protein expressions in K562 cells. Molecular docking revealed strong binding affinity of PAC to p53 protein, further confirmed by molecular dynamics simulation. Discussion: The study presents novel anticancer compounds targeting the p53 ubiquitination pathway, exemplified by PAC. Future perspectives involve further optimization and preclinical studies to validate PAC's potential as an effective anticancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Aiming for the future: The latest advances in targeted therapy for ovarian cancer.
- Author
-
HUANG Shan'gao, WU Yueling, and ZHANG Ying
- Subjects
OVARIAN cancer ,CANCER treatment ,WOMEN'S health - Abstract
Ovarian cancer represents a significant threat to women's health globally, with particularly high recurrence and mortality rates in China's context of gynecological malignancies. The effectiveness of traditional therapeutic approaches for advanced and recurrent ovarian cancer remains quite limited. However, recent studies have highlighted the substantial success of targeted therapies in managing ovarian cancer. This paper delves into both national and international research on ovarian cancer's targeted treatments, examining their mechanisms, applications, current landscape, and the challenges they face. It aims to offer innovative perspectives and directions for ovarian cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. A nationwide neurosurgical inter-disciplinary service for cancer-related refractory pain.
- Author
-
khashan, Morsi, Strauss, Ido, Hochberg, Yehonathan, Brill, Silviu, Tellem, Rotem, Sharon, Haggai, and Hochberg, Uri
- Subjects
CANCER treatment ,NEUROSURGERY ,ABLATION techniques ,INTERPROFESSIONAL relations ,RETROSPECTIVE studies ,CANCER patients ,DESCRIPTIVE statistics ,CANCER pain ,OPERATIVE surgery ,PAIN management ,MEDICAL records ,ACQUISITION of data ,HEALTH care teams ,SPECIALTY hospitals - Abstract
Purpose: Neurosurgical ablative procedures, such as cordotomy and cingulotomy, are often considered irreversible and destructive but can provide an effective and individualized solution for cancer-related refractory pain, when all other approaches have been unsuccessful. This paper provides an in-depth exploration of a novel approach to managing refractory cancer pain. It involves an interdisciplinary team led by a neurosurgeon at a renowned national referral center. Methods: a retrospective analysis of the medical records of all sequential patients who underwent their initial evaluation at our interdisciplinary refractory cancer pain clinic from February 2017 to January 2023. Results: A total of 207 patients were examined in the clinic for a first visit during the study period. All patients were referred to the clinic due to severe pain that was deemed refractory by the referring physician. The mean age was 61 ± 12.3 years, with no significant sex difference (P = 0.58). The mean ECOG Performance Status score was 2.35. Conservative measures had not yet been exhausted in 28 patients (14%) and 9 patients were well controlled (4%). Neurosurgical ablative procedures were recommended for 151 (73%) of the patients. Sixty-six patients (32%) eventually underwent the procedure. 91 patients (44%) received a negative recommendation for surgery. Thirty-five patients (17%) were referred for further invasive procedures at the pain clinic. Conclusion: An Interdisciplinary cooperation between palliative care specialists, pain specialists, and neurosurgeons ensures optimal patient selection and provides safe and effective neurosurgery for the treatment of refractory cancer-related pain. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Mitochondrial inhibitors: a new horizon in breast cancer therapy.
- Author
-
Yalan Yan, Sijie Li, Lanqian Su, Xinrui Tang, Xiaoyan Chen, Xiang Gu, Guanhu Yang, Hao Chi, and Shangke Huang
- Subjects
BREAST cancer ,KREBS cycle ,METABOLIC reprogramming ,CANCER treatment ,MITOCHONDRIA ,AMINO acid metabolism - Abstract
Breast cancer, due to resistance to standard therapies such as endocrine therapy, anti-HER2 therapy and chemotherapy, continues to pose a major health challenge. A growing body of research emphasizes the heterogeneity and plasticity of metabolism in breast cancer. Because differences in subtypes exhibit a bias toward metabolic pathways, targeting mitochondrial inhibitors shows great potential as stand-alone or adjuvant cancer therapies. Multiple therapeutic candidates are currently in various stages of preclinical studies and clinical openings. However, specific inhibitors have been shown to face multiple challenges (e.g., single metabolic therapies, mitochondrial structure and enzymes, etc.), and combining with standard therapies or targeting multiple metabolic pathways may be necessary. In this paper, we review the critical role of mitochondrial metabolic functions, including oxidative phosphorylation (OXPHOS), the tricarboxylic acid cycle, and fatty acid and amino acid metabolism, in metabolic reprogramming of breast cancer cells. In addition, we outline the impact of mitochondrial dysfunction on metabolic pathways in different subtypes of breast cancer and mitochondrial inhibitors targeting different metabolic pathways, aiming to provide additional ideas for the development of mitochondrial inhibitors and to improve the efficacy of existing therapies for breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Clinical and translational implications of immunotherapy in sarcomas.
- Author
-
Recine, Federica, Vanni, Silvia, Bongiovanni, Alberto, Fausti, Valentina, Mercatali, Laura, Miserocchi, Giacomo, Liverani, Chiara, Pieri, Federica, Casadei, Roberto, Cavaliere, Davide, Falbo, Pina Tiziana, Diano, Danila, Ibrahim, Toni, and De Vita, Alessandro
- Subjects
SARCOMA ,TUMOR-infiltrating immune cells ,IMMUNOTHERAPY ,TIME complexity ,CANCER treatment ,SYNOVIOMA - Abstract
Immunotherapy has emerged as promising treatment in sarcomas, but the high variability in terms of histology, clinical behavior and response to treatments determines a particular challenge for its role in these neoplasms. Tumor immune microenvironment (TiME) of sarcomas reflects the heterogeneity of these tumors originating from mesenchymal cells and encompassing more than 100 histologies. Advances in the understanding of the complexity of TiME have led to an improvement of the immunotherapeutic responsiveness in sarcomas, that at first showed disappointing results. The proposed immune-classification of sarcomas based on the interaction between immune cell populations and tumor cells showed to have a prognostic and potential predictive role for immunotherapies. Several studies have explored the clinical impact of immune therapies in the management of these histotypes leading to controversial results. The presence of Tumor Infiltrating Lymphocytes (TIL) seems to correlate with an improvement in the survival of patients and with a higher responsiveness to immunotherapy. In this context, it is important to consider that also immunerelated genes (IRGs) have been demonstrated to have a key role in tumorigenesis and in the building of tumor immune microenvironment. The IRGs landscape in soft tissue and bone sarcomas is characterized by the connection between several tumor-related genes that can assume a potential prognostic and predictive therapeutic role. In this paper, we reviewed the state of art of the principal immune strategies in the management of sarcomas including their clinical and translational relevance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy.
- Author
-
Ivanov, Stanislav, Nano, Olger, Hana, Caroline, Bonano-Rios, Amalia, and Hussein, Atif
- Subjects
ISOCITRATE dehydrogenase ,HOMEOSTASIS ,NICOTINAMIDE adenine dinucleotide phosphate ,KREBS cycle ,ACUTE myeloid leukemia ,CANCER treatment ,OXIDATIVE stress - Abstract
The advent of comprehensive genomic profiling using next-generation sequencing (NGS) has unveiled an abundance of potentially actionable genetic aberrations that have shaped our understanding of the cancer biology landscape. Isocitrate dehydrogenase (IDH) is an enzyme present in the cytosol (IDH1) and mitochondria (IDH2 and IDH3). In the mitochondrion, it catalyzes the irreversible oxidative decarboxylation of isocitrate, yielding the production of α-ketoglutarate and nicotinamide adenine dinucleotide phosphate (NADPH) as well as carbon dioxide (CO
2 ). In the cytosol, IDH catalyzes the decarboxylation of isocitrate to α-ketoglutarate as well as the reverse reductive carboxylation of α-ketoglutarate to isocitrate. These rate-limiting steps in the tricarboxylic acid cycle, as well as the cytoplasmic response to oxidative stress, play key roles in gene regulation, cell differentiation, and tissue homeostasis. Mutations in the genes encoding IDH1 and IDH2 and, less commonly, IDH3 have been found in a variety of cancers, most commonly glioma, acute myeloid leukemia (AML), chondrosarcoma, and intrahepatic cholangiocarcinoma. In this paper, we intend to elucidate the theorized pathophysiology behind IDH isomer mutation, its implication in cancer manifestation, and discuss some of the available clinical data regarding the use of novel IDH inhibitors and their role in therapy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
47. A qualitative study of stakeholders' experiences with and acceptability of a technology‐supported health coaching intervention (SHARE‐S) delivered in coordination with cancer survivorship care.
- Author
-
Price, Sarah N., Houston, Thomas K., Sadasivam, Rajani S., Wentworth, Stacy, Chandler, Allison, Strahley, Ashley, Kittel, Carol, Balakrishnan, Kavitha, Weaver, Kathryn E., Dellinger, Rebecca, Puccinelli‐Ortega, Nicole, Kong, Jinhee, Cutrona, Sarah L., Foley, Kristie L., and Sohl, Stephanie J.
- Subjects
HEALTH coaches ,CANCER treatment ,HEALTH care teams ,HEALTH behavior ,TEXT messages ,MEDICAL care accountability - Abstract
Purpose: Healthy cancer survivorship involves patients' active engagement with preventative health behaviors and follow‐up care. While clinicians and patients have typically held dual responsibility for activating these behaviors, transitioning some clinician effort to technology and health coaches may enhance guideline implementation. This paper reports on the acceptability of the Shared Healthcare Actions & Reflections Electronic systems in survivorship (SHARE‐S) program, an entirely virtual multicomponent intervention incorporating e‐referrals, remotely‐delivered health coaching, and automated text messages to enhance patient self‐management and promote healthy survivorship. Methods: SHARE‐S was evaluated in single group hybrid implementation‐effectiveness pilot study. Patients were e‐referred from the clinical team to health coaches for three health self‐management coaching calls and received text messages to enhance coaching. Semi‐structured qualitative interviews were conducted with 21 patient participants, 2 referring clinicians, and 2 health coaches to determine intervention acceptability (attitudes, appropriateness, suitability, convenience, and perceived effectiveness) and to identify important elements of the program and potential mechanisms of action to guide future implementation. Results: SHARE‐S was described as impactful and convenient. The nondirective, patient‐centered health coaching and mindfulness exercises were deemed most acceptable; text messages were less acceptable. Stakeholders suggested increased flexibility in format, frequency, timing, and length of participation, and additional tailored educational materials. Patients reported tangible health behavior changes, improved mood, and increased accountability and self‐efficacy. Conclusions: SHARE‐S is overall an acceptable and potentially effective intervention that may enhance survivors' self‐management and well‐being. Alterations to tailored content, timing, and dose should be tested to determine impact on acceptability and outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Integrating Chinese medicine into mainstream cancer therapies: a promising future.
- Author
-
Baoyi Ni, Kaiyuan Xue, Jia Wang, Jilai Zhou, Lankang Wang, Xinmiao Wang, Ting Liu, Naijing Ye, and Jiakang Jiang
- Subjects
CHINESE medicine ,CANCER treatment ,ADJUVANT treatment of cancer ,DRUG resistance ,TRADITIONAL medicine - Abstract
Malignant tumors are complex systemic chronic diseases and one of the major causes of human mortality. Targeted therapy, chemotherapy, immunotherapy, and radiotherapy are examples of mainstream allopathic medicine treatments that effective for intermediate and advanced malignant tumors. The ongoing use of conventional allopathic medicine has resulted in adverse responses and drug resistance, which have hampered its efficacy. As an important component of complementary and alternative medicine, Chinese medicine has been found to have antitumor effects and has played an important role in enhancing the therapeutic sensitivity of mainstream allopathic medicine, reducing the incidence of adverse events and improving immune-related functions. The combined application of adjuvant Chinese medicine and mainstream allopathic medicine has begun to gain acceptance and is gradually used in the field of antitumor therapy. Traditional natural medicines and their active ingredients, as well as Chinese patent medicines, have been proven to have excellent therapeutic efficacy and good safety in the treatment of variousmalignant tumors. This paper focuses on the mechanism of action and research progress of combining the above drugs with mainstream allopathic medicine to increase therapeutic sensitivity, alleviate drug resistance, reduce adverse reactions, and improve the body's immune function. To encourage the clinical development and use of Chinese herb adjuvant therapy as well as to provide ideas and information for creating safer and more effective anticancer medication combinations, the significant functions of Chinese herb therapies as adjuvant therapies for cancer treatment are described in detail. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Ginsenosides: an immunomodulator for the treatment of colorectal cancer.
- Author
-
Jianan Qian, Yanyu Jiang, and Hongyi Hu
- Subjects
GINSENOSIDES ,COLORECTAL cancer ,GINSENG ,CHINESE medicine ,CANCER treatment ,TUMOR microenvironment - Abstract
Ginsenosides, the primary bioactive ingredients derived from the root of Panax ginseng, are eagerly in demand for tumor patients as a complementary and alternative drug. Ginsenosides have increasingly become a "hot topic" in recent years due to their multifunctional role in treating colorectal cancer (CRC) and regulating tumor microenvironment (TME). Emerging experimental research on ginsenosides in the treatment and immune regulation of CRC has been published, while no review sums up its specific role in the CRC microenvironment. Therefore, this paper systematically introduces how ginsenosides affect the TME, specifically by enhancing immune response, inhibiting the activation of stromal cells, and altering the hallmarks of CRC cells. In addition, we discuss their impact on the physicochemical properties of the tumor microenvironment. Furthermore, we discuss the application of ginsenosides in clinical treatment as their efficacy in enhancing tumor patient immunity and prolonging survival. The future perspectives of ginsenoside as a complementary and alternative drug of CRC are also provided. This review hopes to open up a new horizon for the cancer treatment of Traditional Chinese Medicine monomers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Exploring the potential of Radiomics in identification and treatment of lung cancer: A systematic evaluation.
- Author
-
Balekai, Raviteja and Holi, Mallikarjun S.
- Subjects
RADIOMICS ,LUNG cancer ,POSITRON emission tomography ,COMPUTED tomography ,CANCER treatment - Abstract
Lung cancer is one of the most serious and life-threatening diseases in the world. Imaging modalities like computed tomography (CT) and Positron emission tomography (PET) play a crucial role in cancer diagnosis. Radiomics is an emerging field in medical imaging that uses advanced computational algorithms to extract quantitative features from medical images. Machine learning makes radiomics method of cancer diagnosis easier and more efficient by automating the process of feature selection and classification, which can save time and reduce the risk of human error in the diagnosis. It has the potential to revolutionize cancer detection by providing clinicians with valuable insights into tumour biology that can help in clinical decision-making and improve patient care outcomes. In this review paper, we primarily summarize the workflow of radiomics studies in the context of lung cancer and discussed the practical uses of radiomics in lung cancer, such as malignant tumour identification, classification of histologic subtypes, identification of tumour genotypes, and prediction of treatment response. Additionally, the paper addresses the key challenges associated with the clinical transition of radiomics, the limitations of current approaches, and potential future directions in this field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.